The Clorox Company (CLX) — Fair Value Analysis

Base-case fair value (P50): $110.47 · Current price: $90.45 · Verdict: Undervalued

The Verdict on CLX

Based on our comprehensive Monte Carlo simulations, Clorox (CLX) is currently Fairly Valued. The stock trades at $90.45, while our median fair value (P50) stands at $110.47. This implies a potential +22.1% from the current trading price. Despite this suggested upside, the stock's valuation within the simulated distribution positions it squarely in a "Fairly Valued" territory, indicating that its current market price closely aligns with its intrinsic value, accounting for a wide range of future scenarios.

How CLX stacks up against Consumer Defensive

As a key player in the Consumer Defensive sector, Clorox's valuation dynamics are often characterized by stability rather than explosive growth. Our analysis indicates CLX holds an average quality tier in terms of its operational and financial health compared to its sector peers. The current price of $90.45 relative to the P50 fair value of $110.47 reflects this stable positioning. While the +22.1% suggests room for appreciation, this is measured against a backdrop of a Consumer Defensive company with an average quality profile, where significant overvaluation or undervaluation might prompt more aggressive positioning.

What this means for investors

Investors considering CLX should interpret its current valuation of $90.45 as largely efficient, given its median fair value of $110.47. The indicated +22.1% provides a modest buffer, aligning with expectations for a stable, average-quality company in the Consumer Defensive sector. Our Monte Carlo analysis, a core component of FairCurve, reveals that while there are both upside and downside scenarios, the stock’s current price reflects a balanced outlook. For a deeper understanding of CLX's full bear-case and bull-case distributions, and to track its fair value as new fundamentals emerge, sign up for a free FairCurve account.